medigraphic.com

2012, Number 5

<< Back Next >>

Cir Cir 2012; 80 (5)

Initial experience in laparoscopic retroperitoneal lymphadenectomy for the management of nonseminomatous testicular cancer

Sosa-Durán EE, Harp-Hasan ZA, García-Rodríguez FM, Bazán-Soto A, Delgado-Ochoa MD, Jiménez-Villanueva X

Language: Spanish
References: 40
Page: 442-447
PDF size: 120.89 Kb.


ABSTRACT

Background: germ cell tumors of the testis represent 1% of all cancers in males. The mean age of occurrence is between 15 and 35 years. Early diagnosis and accuracy of staging are factors that have an impact in survival. According with stage I SO in nonseminoma tumors, there are three management options. Choice among them is based on the risk of recurrence, their morbidity and informed consent of the patient. The objective of this paper is to present the first results of retroperitoneal laparoscopic lymphadenectomy (RLL) in testicular germ cell nonseminoma tumors stage I S-0 at the Oncology Unit of Hospital Juarez de México.
Methods: retrospective study of the data base of patients diagnosed with nonseminomatous testicular cancer Stage I, S-0 and subject to retroperitoneal laparoscopic lymphadenectomy in the period between May 2010 to December 2011.
Results: ten patients underwent transperitoneal retroperitoneal laparoscopic lymphadenectomy with modified limits, ipsilateral to the affected testicle, 70% were stage I-A, showing a nodal count of 15.3 nodes. None suffered from metastases. The followup mean for all patients was 9.6 months. One patient suffered retroperitoneal relapse off lymphadenectomy’s reach 10 months after the original surgery.
Conclusion: retroperitoneal laparoscopic lymphadenectomy is a safe procedure with reasonable morbidity, hospital stay and nodal count. It requires a surgeon expert in laparoscopic techniques.


REFERENCES

  1. Fernández CS, León AG, Herrera TM, Salazar SE, Sánchez DM, Alcalá OR, et al. Perfil epidemiológico de los tumores malignos en México, SINAIS/SINAVE/DGE/SALUD; México 2011. Disponible en: http://www.dgepi.salud.gob.mx/2010/PDFS/PUBLICACIONES/MONOGRAFIAS/00_PEPID_TUMORES_MALIGNOS_MEX_2010_PORTADA.pdf

  2. Siegel R, Naishadham D, Jemal A. Cancer Statistics, 2012 CA. Cancer J Clin 2012;62:10-29.

  3. Hernández-Castellanos V, Camarena-Reynoso HR, Vázquez-Ortega L, Mata MP, Leos-Acosta C, Morales-Montor JG, et al. Manejo de los tumores germinales no seminomatosos en estadio I: análisis comparativo. Rev Mex Urol 2009;69(5):200-205.

  4. Mannuel HD, Mitikiri N, Khan M, Hussain A. Testicular germ cell tumors: biology and clinical update. Curr Opin Oncol 2012;24(3):266-271.

  5. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. The American Joint Committee on Cancer: The 7th ed. of the AJCC Cancer Staging Manual and the Future of TNM. New York, NY: Springer, 2010. p. 457-468.

  6. National Comprehensive Cancer Network, clinical practice guidelines in oncology testicular cancer, 2012. Disponible en: http://www.nccn.org/professionals/physician_gls/pdf/testicular.pdf

  7. Schmoll HJ, Jordan K, Huddart R, Pes MP, Horwich A, Fizazi K, et al. Testicular non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl 5):v147-v154.

  8. Vergouwe Y, Steyerberg EW, Eijkemans MJC, Albers P, Habbema JD. Predictors of Occult Metastasis in Clinical Stage I Nonseminoma: A Systematic Review. J Clin Oncol 2003;21(22):4092-4099.

  9. Kakiashvili DM, Zuniga A, Jewett MAS. High risk NSGCT: case for surveillance. World J Urol 2009;27(4):441-447.

  10. Westermann DH, Studer UE. High-risk clinical stage I nonseminomatous germ cell tumors: the case for chemotherapy. World J Urol 2009;27(4):455-461.

  11. Morash C, Cagiannos I. High-risk clinical stage I NSGCT: the case for RPLND. World J Urol 2009;27(4):449-453.

  12. Nguyen CT, Fu AZ, Gilligan TD, Wells BJ, Klein EA, Kattan MW, et al. Defining the Optimal Treatment for Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer Using Decision Analysis. J Clin Oncol 2010;28(1):119-125.

  13. Roy OP, Kavoussi LR. Testicular cancer: Decision tree model has potential to improve NSGCT management. Nat Rev Urol 2010;7(6):308-310.

  14. Wit R, Fizazi K. Controversies in the Management of Clinical Stage I Testis Cancer. J Clin Oncol 2006;24(35):5482-5492.

  15. Williams SB, McDermott DW, Winston D, Bahnson E, Berry AM, Steele GS, et al. Morbidity of open retroperitoneal lymph node dissection for testicular cancer: contemporary perioperative data. BJU Int 105(7):918-921.

  16. Tarin TV, Sonn G, Shinghal R. Estimating the Risk of Cancer Associated With Imaging Related Radiation During Surveillance for Stage I Testicular Cancer Using Computerized Tomography. J Urol 2009;181(2):627-633.

  17. Fung C, Vaughn DJ. Complications associated with chemotherapy in testicular cancer management. Nat Rev Urol 2011;8(4):213-222.

  18. Singhera M, Lees K, Huddart R, Horwich A. Minimizing toxicity in early-stage testicular cancer treatment. Expert Rev Anticancer Ther 2012;12(2):185-193.

  19. Steiner H, Peschel R, Bartsch G. Laparoscopic retroperitoneal lymph node dissection: current concepts and limitations. BJU Int 2009:104(9 Pt B):1376-1380.

  20. Kenney PA, Tuerk IA. Complications of laparoscopic retroperitoneal lymph node dissection in testicular cancer. World J Urol 2008:26(6):561-569.

  21. Beck SDW, Peterson MD, Bihrle R, Donohue JP, Foster RS. Short- Term Morbidity of Primary Retroperitoneal Lymph Node Dissection in a Contemporary Group of Patients. J Urol 2007;178(2):504-506.

  22. Leibovitch I, Mor Y, Golomb J, Ramon J. The diagnosis and management of postoperative chylous ascites. J Urol 2002;167(2 Pt 1):449-457.

  23. Lattouf JB, Jeschke S, Janetschek G. Laparoscopic retroperitoneal lymph node dissection: technique. BJU Int 2007;100(6):1415-1429.

  24. Corvin S, Sturm W, Kuczyk M, Anastasiadis AG, Stenzl A. Laparoscopic retroperitoneal lymphadenectomy in the management of lowstage testicular cancer: Technique and results. Minim Invasive Ther Allied Technol 2005;14(2):52-56.

  25. Large MC, Sheinfeld J, Eggener SE. Retroperitoneal lymph node dissection: reassessment of modified templates. BJU Int 2009;104(9 Pt B):1369-1375.

  26. Höltl L, Peschel R, Knapp R, Janetschek G, Steiner H, Hittmair A, et al. Primary lymphatic metastatic spread in testicular cancer occurs ventral to the lumbar vessels. Urology 2002;59(1):114-118.

  27. Chang SS, Mohseni HF, Leon A, Sheinfeld J. Paracolic recurrence: the importance of wide excision of the spermatic cord at retroperitoneal lymph node dissection. J Urol 2002;167(1):94-96.

  28. Peschel R, Gettman MT, Neururer R, Hobisch A, Bartsch G. Laparoscopic retroperitoneal lymph node dissection: description of the nerve-sparing technique. Urology 2002;60(2):339-343.

  29. Jewett MAS, Groll RJ. Nerve-Sparing Retroperitoneal Lymphadenectomy. Urol Clin North Am 2007;34(2):149-158.

  30. Tarin T, Carver B, Sheinfeld J. The role of lymphadenectomy for testicular cancer: indications, controversies, and complications. Urol Clin North Am 2011;38(4):439-449.

  31. Thompson RH, Carver BS, Bosl GJ, Bajorin D, Motzer R, Feldman DR, et al. Contemporary Lymph Node Counts During Primary Retroperitoneal Lymph Node Dissection. Urology 2011;77(2):368-372.

  32. Stephenson AJ, Aprikian AG, Gilligan TD, Oldenburg J, Powles T, Toner GC, et al. Management of Low-stage Nonseminomatous Germ Cell Tumors of Testis: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009. Urology 2011;78(Suppl 4):S444-S455.

  33. Hulbert JC, Fraley EE. Laparoscopic Retroperitoneal Lymphadenectomy: New Approach to Pathologic Staging of Clinical Stage I Germ Cell Tumors of the Testis. J Endourol 1992;6(2):123-125.

  34. Rassweiler JJ, Scheitlin W, Heidenreich A, Laguna MP, Janetschek G. Laparoscopic Retroperitoneal Lymph Node Dissection: Does It Still Have a Role in the Management of Clinical Stage I Nonseminomatous Testis Cancer? A European Perspective. Eur Urol 2008;54(5):1004-1015.

  35. Sun M, Abdollah F, Budaüs L, Liberman D, Tian Z, Morgan M, et al. Trends of Retroperitoneal Lymphadenectomy Use in Patients with Nonseminomatous Germ Cell Tumor of the Testis: A Population-Based Study. Ann Surg Oncol 2011;18(10):2997-3004.

  36. Hyams ES, Pierorazio P, Proteek O, Sroka M, Kavoussi LR, Allaf ME. Laparoscopic Retroperitoneal Lymph Node Dissection for Clinical Stage I Nonseminomatous Germ Cell Tumor: A Large Single Institution Experience. J Urol 2012;187(2):487-492.

  37. Gardner MW, Roytman TM, Chen C, Brandes SB, Kibel AS, Grubb RL, et al. Laparoscopic Retroperitoneal Lymph Node Dissection for Low-Stage Cancer: A Washington University Update. J Endourol 2011;25(11):1753-1757.

  38. Sturgeon JF, Moore MJ, Kakiashvili DM, Duran I, Anson-Cartwright LC, Berthold DR, et al. Non-Risk-Adapted Surveillance in Clinical Stage I Nonseminomatous Germ Cell Tumors: The Princess Margaret Hospital's Experience. Eur Urol 2011;59(4):556-562.

  39. Castillo OA, Sánchez-Salas R, Secin FP, Campero JM, Fonerón A, Vidal-Mora I. Primary laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ-cell testis tumor. Actas Urol Esp 2011;35(1):22-28.

  40. Roy OP, Duty BD, Kavoussi LR. Minimally invasive retroperitoneal lymph node dissection for testicular cancer. Urol Clin North Am 2011;38(4):451-458.




2020     |     www.medigraphic.com